JP2020511469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511469A5 JP2020511469A5 JP2019550688A JP2019550688A JP2020511469A5 JP 2020511469 A5 JP2020511469 A5 JP 2020511469A5 JP 2019550688 A JP2019550688 A JP 2019550688A JP 2019550688 A JP2019550688 A JP 2019550688A JP 2020511469 A5 JP2020511469 A5 JP 2020511469A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- effective amount
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023030606A JP2023071824A (ja) | 2017-03-14 | 2023-03-01 | 補体が媒介する疾患および障害を処置するための方法 |
| JP2025014511A JP2025072437A (ja) | 2017-03-14 | 2025-01-31 | 補体が媒介する疾患および障害を処置するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471190P | 2017-03-14 | 2017-03-14 | |
| US62/471,190 | 2017-03-14 | ||
| US201762553059P | 2017-08-31 | 2017-08-31 | |
| US62/553,059 | 2017-08-31 | ||
| PCT/US2018/022462 WO2018170145A1 (en) | 2017-03-14 | 2018-03-14 | Methods for treating complement-mediated diseases and disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023030606A Division JP2023071824A (ja) | 2017-03-14 | 2023-03-01 | 補体が媒介する疾患および障害を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511469A JP2020511469A (ja) | 2020-04-16 |
| JP2020511469A5 true JP2020511469A5 (cg-RX-API-DMAC7.html) | 2021-04-22 |
| JP7293122B2 JP7293122B2 (ja) | 2023-06-19 |
Family
ID=61873979
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550688A Active JP7293122B2 (ja) | 2017-03-14 | 2018-03-14 | 補体が媒介する疾患および障害を処置するための方法 |
| JP2023030606A Pending JP2023071824A (ja) | 2017-03-14 | 2023-03-01 | 補体が媒介する疾患および障害を処置するための方法 |
| JP2025014511A Pending JP2025072437A (ja) | 2017-03-14 | 2025-01-31 | 補体が媒介する疾患および障害を処置するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023030606A Pending JP2023071824A (ja) | 2017-03-14 | 2023-03-01 | 補体が媒介する疾患および障害を処置するための方法 |
| JP2025014511A Pending JP2025072437A (ja) | 2017-03-14 | 2025-01-31 | 補体が媒介する疾患および障害を処置するための方法 |
Country Status (14)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| ES2912396T3 (es) | 2012-11-02 | 2022-05-25 | Bioverativ Usa Inc | Anticuerpos anti-C1s del complemento y uso de los mismos |
| EP4212175A1 (en) | 2015-04-06 | 2023-07-19 | Bioverativ USA Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| IL326479A (en) | 2016-10-12 | 2026-04-01 | Bioverativ Usa Inc | Anti-c1s antibodies and methods of use thereof |
| PL3893924T3 (pl) | 2018-12-13 | 2025-01-13 | argenx BV | Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| JP2023503611A (ja) * | 2019-11-26 | 2023-01-31 | オメロス コーポレーション | 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法 |
| FI129383B (en) | 2020-06-15 | 2022-01-31 | Faron Pharmaceuticals Oy | Stable anti-clever-1 antibody formulation |
| BR112023001942A2 (pt) * | 2020-08-06 | 2023-02-28 | Bioverativ Usa Inc | Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento |
| TW202304508A (zh) | 2021-03-31 | 2023-02-01 | 美商百歐維拉提夫美國公司 | 減少冷凝集素疾病患者之手術相關溶血 |
| US12252550B2 (en) | 2021-05-20 | 2025-03-18 | Dianthus Therapeutics Opco, Inc. | Antibodies that bind to C1S and uses thereof |
| CN117642431B (zh) | 2021-07-13 | 2025-07-15 | 迈威(美国)生物治疗有限公司 | 抗c1s抗体和其用途 |
| CN114874329A (zh) * | 2022-05-19 | 2022-08-09 | 江苏大学 | 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用 |
| MA71249A (fr) | 2022-06-24 | 2025-04-30 | Bioverativ Usa Inc. | Méthodes de traitement de maladies médiées par complément |
| TW202426490A (zh) | 2022-11-21 | 2024-07-01 | 美商黛安瑟斯醫療運營公司 | 結合ｃ１ｓ之抗體及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| ES2912396T3 (es) * | 2012-11-02 | 2022-05-25 | Bioverativ Usa Inc | Anticuerpos anti-C1s del complemento y uso de los mismos |
| WO2015084999A1 (en) * | 2013-12-06 | 2015-06-11 | True North Therapeutics, Inc. | Complement component biomarker assays |
-
2018
- 2018-03-14 SG SG11201907583TA patent/SG11201907583TA/en unknown
- 2018-03-14 KR KR1020197029545A patent/KR102934707B1/ko active Active
- 2018-03-14 BR BR112019018950-5A patent/BR112019018950A2/pt unknown
- 2018-03-14 CA CA3055781A patent/CA3055781A1/en active Pending
- 2018-03-14 KR KR1020267006425A patent/KR20260039796A/ko active Pending
- 2018-03-14 TW TW107108658A patent/TWI848905B/zh active
- 2018-03-14 EP EP18715381.2A patent/EP3596121A1/en active Pending
- 2018-03-14 AU AU2018236267A patent/AU2018236267B2/en active Active
- 2018-03-14 MX MX2019010994A patent/MX2019010994A/es unknown
- 2018-03-14 US US16/494,267 patent/US20210115116A1/en not_active Abandoned
- 2018-03-14 WO PCT/US2018/022462 patent/WO2018170145A1/en not_active Ceased
- 2018-03-14 TW TW113122096A patent/TW202513092A/zh unknown
- 2018-03-14 IL IL269174A patent/IL269174B2/en unknown
- 2018-03-14 CN CN201880029619.1A patent/CN110753701A/zh active Pending
- 2018-03-14 JP JP2019550688A patent/JP7293122B2/ja active Active
- 2018-03-14 CR CR20190468A patent/CR20190468A/es unknown
- 2018-03-14 IL IL325084A patent/IL325084A/en unknown
-
2019
- 2019-09-13 MX MX2025010483A patent/MX2025010483A/es unknown
-
2023
- 2023-03-01 JP JP2023030606A patent/JP2023071824A/ja active Pending
-
2025
- 2025-01-31 JP JP2025014511A patent/JP2025072437A/ja active Pending
- 2025-06-12 AU AU2025204392A patent/AU2025204392A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7628996B2 (ja) | 改善された血清アルブミン結合剤 | |
| US20240124599A1 (en) | Anti-bcma heavy chain-only antibodies | |
| US10618976B2 (en) | SIRP-α agonist antibody | |
| US11434299B2 (en) | Anti-BCMA heavy chain-only antibodies | |
| JP2026053563A (ja) | 補体関連疾患のための融合タンパク質構築物 | |
| US11873336B2 (en) | Heavy chain antibodies binding to CD22 | |
| JP2018520139A (ja) | エクリズマブまたはエクリズマブバリアントでのワクチン接種に従って患者を処置するための方法 | |
| JP2025072437A (ja) | 補体が媒介する疾患および障害を処置するための方法 | |
| CN111630065A (zh) | 抗c5抗体组合及其用途 | |
| CN112442123B (zh) | 抗cd47的单克隆抗体及其用途 | |
| EP3313417A1 (en) | Methods of treating autoimmune and alloimmune disorders | |
| CN116724236A (zh) | 患有补体介导的疾病的受试者中的炎性细胞因子和疲劳 | |
| JP7158376B2 (ja) | インターロイキン－６のヒト受容体に結合することができる抗体またはその抗原結合フラグメント | |
| RU2824402C2 (ru) | Конструкции слитого белка для заболевания, связанного с комплементом | |
| WO2025128263A9 (en) | Anti-pd-1 monoclonal antibody and methods of preparation thereof | |
| HK40125060A (en) | Formulations for anti-c1q antibodies | |
| TW202615092A (zh) | 抗ｃ２抗體及其用途 | |
| NZ749153B2 (en) | Anti-c5 antibodies and uses thereof | |
| BR112016025319B1 (pt) | Anticorpo anti-fcrn isolado, polinucleotídeos, vetor de expressão recombinante, composições e método para detectar fcrn in vitro |